SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Alan C Moss, Yvonne Lillis, Jessica B Edwards George, Niteesh K Choudhry, Anders H Berg, Adam S Cheifetz, Gary Horowitz, Dan A Leffler, Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD, The American Journal of Gastroenterology, 2014,

    CrossRef

  2. 2
    Mark P. Connolly, Johan P. Kuyvenhoven, Maarten J. Postma, Sandy K. Nielsen, Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing, Journal of Crohn's and Colitis, 2014, 8, 5, 357

    CrossRef

  3. 3
    David Gillespie, Kerenza Hood, Daniel Farewell, Rachel Stenson, Christopher Probert, A. Barney Hawthorne, Electronic Monitoring of Medication Adherence in a 1-year Clinical Study of 2 Dosing Regimens of Mesalazine for Adults in Remission with Ulcerative Colitis, Inflammatory Bowel Diseases, 2014, 20, 1, 82

    CrossRef

  4. 4
    Vered Abitbol, Pierre Lahmek, Anne Buisson, Alain Olympie, Cécile Poupardin, Stanislas Chaussade, Bruno Lesgourgues, Stéphane Nahon, Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, 2014, 26, 3, 288

    CrossRef

  5. 5
    Gary R. Lichtenstein, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes, Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative Colitis, Inflammatory Bowel Diseases, 2014, 20, 8, 1399

    CrossRef

  6. 6
    Kathy J. Wheeler, Mary Ellen Roberts, Mary B. Neiheisel, Medication adherence part two: Predictors of nonadherence and adherence, Journal of the American Association of Nurse Practitioners, 2014, 26, 4
  7. 7
    Angelo Viscido, Annalisa Capannolo, Giovanni Latella, Renzo Caprilli, Giuseppe Frieri, Nanotechnology in the treatment of inflammatory bowel diseases, Journal of Crohn's and Colitis, 2014, 8, 9, 903

    CrossRef

  8. 8
    Valérie Pittet, Gerhard Rogler, Christian Mottet, Florian Froehlich, Pierre Michetti, Philippe de Saussure, Bernard Burnand, John-Paul Vader, Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients, Scandinavian Journal of Gastroenterology, 2014, 49, 6, 662

    CrossRef

  9. 9
    Dalapathi Gugulothu, Aditya Kulkarni, Vandana Patravale, Prajakta Dandekar, pH-Sensitive Nanoparticles of Curcumin–Celecoxib Combination: Evaluating Drug Synergy in Ulcerative Colitis Model, Journal of Pharmaceutical Sciences, 2014, 103, 2
  10. 10
    F. Seibold, N. Fournier, C. Beglinger, C. Mottet, V. Pittet, G. Rogler, Topical therapy is underused in patients with ulcerative colitis, Journal of Crohn's and Colitis, 2014, 8, 1, 56

    CrossRef

  11. 11
    Anne E Gifford, Anders H Berg, Conor Lahiff, Adam S Cheifetz, Gary Horowitz, Alan C Moss, A Random Urine Test Can Identify Patients at Risk of Mesalamine Non-Adherence: A Prospective Study, The American Journal of Gastroenterology, 2013, 108, 2, 249

    CrossRef

  12. 12
    Chi Zhang, Miao Jiang, Aiping Lu, Considerations of Traditional Chinese Medicine as Adjunct Therapy in the Management of Ulcerative Colitis, Clinical Reviews in Allergy & Immunology, 2013, 44, 3, 274

    CrossRef

  13. 13
    A. Robinson, M. Hankins, G. Wiseman, M. Jones, Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse, Alimentary Pharmacology & Therapeutics, 2013, 38, 5
  14. 14
    Jean Lachaine, Linnette Yen, Catherine Beauchemin, Paul Hodgkins, Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database, BMC Gastroenterology, 2013, 13, 1, 23

    CrossRef

  15. 15
    Stefan Schreiber, Julián Panés, Edouard Louis, Derek Holley, Mandy Buch, Kristine Paridaens, National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey, Journal of Crohn's and Colitis, 2013, 7, 6, 497

    CrossRef

  16. 16
    B. Flourié, H. Hagège, G. Tucat, D. Maetz, X. Hébuterne, J. P. Kuyvenhoven, T. G. Tan, M. J. Pierik, A. A. M. Masclee, O. Dewit, C. S. Probert, D. Aoucheta, Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2013, 37, 8
  17. 17
    Yun-Seong Kang, So Young Kim, Min Ho Jo, Hyoun Woo Kang, Jun Kyu Lee, Yun Jeong Lim, Moon Soo Koh, Jin Ho Lee, Chang Hun Yang, Jae Hak Kim, The Association between the Therapeutic Agent and the Compliance of the Patients with Inflammatory Bowel Diseases, The Korean Journal of Gastroenterology, 2013, 61, 6, 313

    CrossRef

  18. 18
    P. Frei, G. Rogler, Topische Therapie bei chronisch-entzündlichen Darmerkrankungen, Der Gastroenterologe, 2013, 8, 3, 197

    CrossRef

  19. 19
    A. V. Weizman, E. Ahn, R. Thanabalan, W. Leung, K. Croitoru, M. S. Silverberg, A. Hillary Steinhart, G. C. Nguyen, Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2012, 35, 3
  20. 20
    Wojciech Blonski, Anna M. Buchner, Gary R. Lichtenstein, Clinical Predictors of Aggressive/Disabling Disease: Ulcerative Colitis and Crohn Disease, Gastroenterology Clinics of North America, 2012, 41, 2, 443

    CrossRef

  21. 21
    Aki Kawakami, Makoto Tanaka, Ryota Ochiai, Makoto Naganuma, Yasushi Iwao, Toshifumi Hibi, Keiko Kazuma, Difficulties in Taking Aminosalicylates for Patients With Ulcerative Colitis, Gastroenterology Nursing, 2012, 35, 1, 24

    CrossRef

  22. 22
    Paul A. Rufo, Lee A. Denson, Francisco A. Sylvester, Eva Szigethy, Pushpa Sathya, Ying Lu, Ghassan T. Wahbeh, Laureen M. Sena, William A. Faubion, Health Supervision in the Management of Children and Adolescents With IBD, Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 1, 93

    CrossRef

  23. 23
    Esther Garcia-Planella, Míriam Mañosa, Manuel Van Domselaar, Jordi Gordillo, Yamile Zabana, Eduard Cabré, Antonio López San Román, Eugeni Domènech, Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids, Digestive and Liver Disease, 2012, 44, 3, 206

    CrossRef

  24. 24
    Maggie Ham, Alan C Moss, Mesalamine in the treatment and maintenance of remission of ulcerative colitis, Expert Review of Clinical Pharmacology, 2012, 5, 2, 113

    CrossRef

  25. 25
    G. R. Lichtenstein, S. Zakko, G. L. Gordon, U. Murthy, S. Sedghi, R. Pruitt, K. Merchant, E. Bortey, W. P. Forbes, Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials, Alimentary Pharmacology & Therapeutics, 2012, 36, 2
  26. 26
    Sara N Horst, Sunanda Kane, Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis, Expert Opinion on Pharmacotherapy, 2012, 13, 15, 2225

    CrossRef

  27. You have free access to this content27
    Brian G. Feagan, John K. MacDonald, Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis, Inflammatory Bowel Diseases, 2012, 18, 9
  28. 28
    A. Barney Hawthorne, Rachel Stenson, David Gillespie, Edwin T. Swarbrick, Anjan Dhar, Kapil C. Kapur, Kerry Hood, Chris S.J. Probert, One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis, Inflammatory Bowel Diseases, 2012, 18, 10
  29. 29
    Laurie Keefer, Bethany Doerfler, Caroline Artz, Optimizing management of Crohn's disease within a project management framework: Results of a pilot study, Inflammatory Bowel Diseases, 2012, 18, 2
  30. 30
    Stefan Schreiber, Julián Panés, Edouard Louis, Derek Holley, Mandy Buch, Kristine Paridaens, Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey, BMC Gastroenterology, 2012, 12, 1, 108

    CrossRef

  31. 31
    Stéphane Nahon, Pierre Lahmek, Christelle Durance, Alain Olympie, Bruno Lesgourgues, Jean-Frédéric Colombel, Jean-Pierre Gendre, Risk factors of anxiety and depression in inflammatory bowel disease, Inflammatory Bowel Diseases, 2012, 18, 11
  32. 32
    Derrick J. Stobaugh, Parakkal Deepak, Matthew Thorpe, Bruce Hannon, Eli D. Ehrenpreis, Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis, Inflammatory Bowel Diseases, 2012, 18, 12
  33. 33
    Sunanda Kane, Seymour Katz, M. Mazen Jamal, Michael Safdi, Ben Dolin, Dory Solomon, Mary Palmen, Karen Barrett, Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis, Inflammatory Bowel Diseases, 2012, 18, 6
  34. 34
    Hans Herfarth, The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis, Digestive Diseases, 2012, 30, s2, 55

    CrossRef

  35. 35
    Pascal Frei, Luc Biedermann, Christine N. Manser, Maike Wilk, Michael Manz, Stephan R. Vavricka, Gerhard Rogler, Topical Therapies in Inflammatory Bowel Disease, Digestion, 2012, 86, s1, 36

    CrossRef

  36. 36
    Ingrid Ordás, Lars Eckmann, Mark Talamini, Daniel C Baumgart, William J Sandborn, Ulcerative colitis, The Lancet, 2012, 380, 9853, 1606

    CrossRef

  37. 37
    Sharon Dudley-Brown, Kathy Baker, Ulcerative Colitis From Patientsʼ Viewpoint, Gastroenterology Nursing, 2012, 35, 1, 54

    CrossRef

  38. 38
    Jeremy Adler, Arnold G. Coran, Daniel H. Teitelbaum, Pediatric Surgery, 2012,

    CrossRef

  39. 39
    Arvind J. Trindade, Adam Ehrlich, Asher Kornbluth, Thomas A. Ullman, Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence, Inflammatory Bowel Diseases, 2011, 17, 2
  40. 40
    Anne Prenzler, Linnette Yen, Thomas Mittendorf, J-Matthias von der Schulenburg, Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine, BMC Health Services Research, 2011, 11, 1, 157

    CrossRef

  41. 41
    Arvind J. Trindade, Donald E. Morisky, Adam C. Ehrlich, Andrew Tinsley, Thomas A. Ullman, Current Practice and Perception of Screening for Medication Adherence in Inflammatory Bowel Disease, Journal of Clinical Gastroenterology, 2011, 45, 10, 878

    CrossRef

  42. 42
    Antonio Tursi, Raymond E. Joseph, Paul Streck, Expanding Applications: The Potential Usage of 5-Aminosalicylic Acid in Diverticular Disease, Digestive Diseases and Sciences, 2011, 56, 11, 3112

    CrossRef

  43. 43
    Eva Szigethy, Laura McLafferty, Alka Goyal, Inflammatory Bowel Disease, Pediatric Clinics of North America, 2011, 58, 4, 903

    CrossRef

  44. 44
    Jane M Andrews, Le plus ca change: Why we need better biomarkers to predict outcomes in ulcerative colitis, Journal of Gastroenterology and Hepatology, 2011, 26, 7
  45. 45
    L. Leifeld, R. Pfützer, J. Morgenstern, P. R. Gibson, Y. Marakhouski, R. Greinwald, R. Mueller, W. Kruis, Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis, Alimentary Pharmacology & Therapeutics, 2011, 34, 9
  46. 46
    Alexander C Ford, Khurram J Khan, William J Sandborn, Sunanda V Kane, Paul Moayyedi, Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, 2011, 106, 12, 2070

    CrossRef

  47. 47
    Kirstin M. Taylor, Peter M. Irving, Optimization of conventional therapy in patients with IBD, Nature Reviews Gastroenterology & Hepatology, 2011, 8, 11, 646

    CrossRef

  48. 48
    S. P. L. Travis, P. D. R. Higgins, T. Orchard, C. J. Van Der Woude, R. Panaccione, A. Bitton, C. O’Morain, J. Panés, A. Sturm, W. Reinisch, M. A. Kamm, G. D’Haens, Review article: defining remission in ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2011, 34, 2
  49. 49
    Stéphane Nahon, Pierre Lahmek, Catherine Saas, Christelle Durance, Alain Olympie, Bruno Lesgourgues, Jean-Pierre Gendre, Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: Results of the ISSEO survey, Inflammatory Bowel Diseases, 2011, 17, 6
  50. 50
    Sunanda V. Kane, Michael Sumner, Dory Solomon, Matthew Jenkins, Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database, Digestive Diseases and Sciences, 2011, 56, 12, 3463

    CrossRef

  51. 51
    Gary R. Lichtenstein, Heidi C. Waters, Jenna Kelly, Susan S. McDonald, Elaine L. Zanutto, David Hendricks, Mirza I. Rahman, Assessing Drug Treatment Preferences of Patients with Crohnʼs Disease, The Patient: Patient-Centered Outcomes Research, 2010, 3, 2, 113

    CrossRef

  52. 52
    Irene Sonu, Ming Valerie Lin, Wojciech Blonski, Gary R. Lichtenstein, Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel Disease, Gastroenterology Clinics of North America, 2010, 39, 3, 559

    CrossRef

  53. 53
    Tilo Andus, Andreas Kocjan, Moritz Müser, Andrey Baranovsky, Tatyana L. Mikhailova, Tatyana D. Zvyagintseva, Andrey E. Dorofeyev, Yurii S. Lozynskyy, Ingolf Cascorbi, Manfred Stolte, Michael Vieth, Karin Dilger, Ralf Mohrbacher, Roland Greinwald, Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis, Inflammatory Bowel Diseases, 2010, 16, 11
  54. 54
    C A Jackson, J Clatworthy, A Robinson, Rob Horne, Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review, The American Journal of Gastroenterology, 2010, 105, 3, 525

    CrossRef

  55. 55
    Fernando Bermejo, Antonio López-San Román, Alicia Algaba, Iván Guerra, Paz Valer, Silvia García-Garzón, Belén Piqueras, Carlos Villa, Andrea Bermejo, José L. Rodríguez-Agulló, Factors that modify therapy adherence in patients with inflammatory bowel disease, Journal of Crohn's and Colitis, 2010, 4, 4, 422

    CrossRef

  56. 56
    Alan C. Moss, Nabeel Chaudhary, Melissa Tukey, Jahvari Junior, Didia Cury, Kenneth R. Falchuk, Adam S. Cheifetz, Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis — A prospective study, Journal of Crohn's and Colitis, 2010, 4, 2, 171

    CrossRef

  57. 57
    Gary R. Lichtenstein, Paul Rutgeerts, Importance of mucosal healing in ulcerative colitis, Inflammatory Bowel Diseases, 2010, 16, 2
  58. 58
    Eva Szigethy, Laura McLafferty, Alka Goyal, Inflammatory Bowel Disease, Child and Adolescent Psychiatric Clinics of North America, 2010, 19, 2, 301

    CrossRef

  59. 59
    Steven J Bernick, Sunanda Kane, Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients, Expert Review of Clinical Immunology, 2010, 6, 4, 677

    CrossRef

  60. 60
    Spencer D Dorn, Mid-Level Providers in Gastroenterology, The American Journal of Gastroenterology, 2010, 105, 2, 246

    CrossRef

  61. 61
    Jill Olmstead, Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis, Journal of the American Academy of Nurse Practitioners, 2010, 22, 11
  62. 62
    Perla Bertomoro, Sara Renna, Mario Cottone, Gabriele Riegler, Fabrizio Bossa, Licio Giglio, Luca Pastorelli, Claudio Papi, Fabiana Castiglione, Erika Angelucci, Roberta Pica, Maria Carla Di Paolo, Renata D'Incà, Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IG-IBD study, Journal of Crohn's and Colitis, 2010, 4, 3, 291

    CrossRef

  63. 63
    D. R. Van Langenberg, P. R. Gibson, Systematic review: fatigue in inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2010, 32, 2
  64. 64
    Paul F. Cook, Suzie Emiliozzi, Dana El-Hajj, Mishcha M. McCabe, Telephone nurse counseling for medication adherence in ulcerative colitis: A preliminary study, Patient Education and Counseling, 2010, 81, 2, 182

    CrossRef

  65. You have free access to this content65
    M. P. THORPE, E. D. EHRENPREIS, K. S. PUTT, B. HANNON, A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol), Alimentary Pharmacology & Therapeutics, 2009, 29, 11
  66. 66
    Fernando Bermejo San José, Antonio López San Román, Alicia Algaba García, Adhesión al tratamiento en la enfermedad inflamatoria intestinal: estrategias para mejorarla, Gastroenterología y Hepatología, 2009, 32, 31

    CrossRef

  67. 67
    Mark P. Connolly, Sandy K. Nielsen, Craig J. Currie, Chris D. Poole, Simon P.L. Travis, An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial, Journal of Crohn's and Colitis, 2009, 3, 1, 32

    CrossRef

  68. 68
    T. MOSHKOVSKA, M. A. STONE, J. CLATWORTHY, R. M. SMITH, J. BANKART, R. BAKER, J. WANG, R. HORNE, J. F. MAYBERRY, An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements, Alimentary Pharmacology & Therapeutics, 2009, 30, 11-12
  69. 69
    C. PRANTERA, A. KOHN, M. CAMPIERI, R. CAPRILLI, M. COTTONE, F. PALLONE, V. SAVARINO, G. C. STURNIOLO, M. VECCHI, A. ARDIA, S. BELLINVIA, Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®, Alimentary Pharmacology & Therapeutics, 2009, 30, 9
  70. 70
    Michael A. Kamm, Gary R. Lichtenstein, William J. Sandborn, Stefan Schreiber, Kirstin Lees, Karen Barrett, Raymond Joseph, Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis, Inflammatory Bowel Diseases, 2009, 15, 1
  71. 71
    J. E. BAARS, Z. ZELINKOVA, P. B. F. MENSINK, T. MARKUS, C. W. N. LOOMAN, E. J. KUIPERS, C. J. VAN DER WOUDE, High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study, Alimentary Pharmacology & Therapeutics, 2009, 30, 8
  72. 72
    David T. Rubin, Corey A. Siegel, Sunanda V. Kane, David G. Binion, Remo Panaccione, Marla C. Dubinsky, Edward V. Loftus, Joseph Hopper, Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey, Inflammatory Bowel Diseases, 2009, 15, 4
  73. 73
    Rob Horne, Rhian Parham, Richard Driscoll, Andrew Robinson, Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease, Inflammatory Bowel Diseases, 2009, 15, 6
  74. 74
    Christine A. Karwowski, David Keljo, Eva Szigethy, Strategies to improve quality of life in adolescents with inflammatory bowel disease, Inflammatory Bowel Diseases, 2009, 15, 11
  75. 75
    J. M. ANDREWS, S. P. L. TRAVIS, P. R. GIBSON, C. GASCHE, Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?, Alimentary Pharmacology & Therapeutics, 2009, 29, 5
  76. 76
    P. D. R. HIGGINS, D. T. RUBIN, K. KAULBACK, P. S. SCHOENFIELD, S. V. KANE, Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares, Alimentary Pharmacology & Therapeutics, 2009, 29, 3
  77. 77
    Zunwu Zhang, Hugh Kennedy, Ulcerative colitis: current medical therapy and strategies for improving medication adherence, European Journal of Gastroenterology & Hepatology, 2009, 21, 1, 1

    CrossRef

  78. 78
    Christina H. Vlahou, Lindsey L. Cohen, Amanda M. Woods, Jeffrey D. Lewis, Benjamin D. Gold, Age and Body Satisfaction Predict Diet Adherence in Adolescents with Inflammatory Bowel Disease, Journal of Clinical Psychology in Medical Settings, 2008, 15, 4, 278

    CrossRef

  79. 79
    Beatriz Sicilia Aladrén, Enfermedad inflamatoria intestinal. ¿Hay que administrar los aminosalicilatos en una sola dosis diaria en la colitis ulcerosa?, Gastroenterología y Hepatología, 2008, 31, 6, 396

    CrossRef

  80. 80
    Daniel Leffler, Adam Chiefetz, Forecasting the recurrence of ulcerative colitis: Can U.C. the future?, Inflammatory Bowel Diseases, 2008, 14, 3
  81. 81
    Stefan Schreiber, Michael A Kamm, Gary R Lichtenstein, Mesalamine with MMX™ technology for the treatment of ulcerative colitis, Expert Review of Gastroenterology & Hepatology, 2008, 2, 3, 299

    CrossRef

  82. 82
    Mary Y Hu, Mark A Peppercorn, MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis, Expert Opinion on Pharmacotherapy, 2008, 9, 6, 1049

    CrossRef

  83. 83
    William J. Sandborn, Oral 5-ASA Therapy in Ulcerative Colitis, Journal of Clinical Gastroenterology, 2008, 42, 4, 338

    CrossRef

  84. 84
    E. Jan Irvine, Quality of life of patients with ulcerative colitis: Past, present, and future, Inflammatory Bowel Diseases, 2008, 14, 4
  85. 85
    G. R. LICHTENSTEIN, M. A. KAMM, Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa, Alimentary Pharmacology & Therapeutics, 2008, 28, 6
  86. 86
    A. ROBINSON, Review article: improving adherence to medication in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2008, 27,
  87. 87
    A. B. HAWTHORNE, G. RUBIN, S. GHOSH, Review article: medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies, Alimentary Pharmacology & Therapeutics, 2008, 27, 12
  88. 88
    Sunanda V Kane, Strategies to Improve Adherence and Outcomes in Patients with Ulcerative Colitis, Drugs, 2008, 68, 18, 2601

    CrossRef

  89. 89
    Karen S. Ingersoll, Jessye Cohen, The impact of medication regimen factors on adherence to chronic treatment: a review of literature, Journal of Behavioral Medicine, 2008, 31, 3, 213

    CrossRef

  90. 90
    Lisa Turnbough, Lindsay Wilson, ???Take Your Medicine???, Gastroenterology Nursing, 2007, 30, 3, 212

    CrossRef

  91. 91
    Richard B. Gearry, Yousef Ajlouni, Sanjay Nandurkar, John H. Iser, Peter R. Gibson, 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: A survey of the opinions and practice of Australian gastroenterologists, Inflammatory Bowel Diseases, 2007, 13, 8
  92. 92
    B. BOKEMEYER, A. TEML, C. ROGGEL, P. HARTMANN, C. FISCHER, E. SCHAEFFELER, M. SCHWAB, Adherence to thiopurine treatment in out-patients with Crohn’s disease, Alimentary Pharmacology & Therapeutics, 2007, 26, 2
  93. 93
    Cyrus P. Tamboli, Current Medical Therapy for Chronic Inflammatory Bowel Diseases, Surgical Clinics of North America, 2007, 87, 3, 697

    CrossRef

  94. 94
    James F. Jackson, Asher Kornbluth, Do Black and Hispanic Americans With Inflammatory Bowel Disease (IBD) Receive Inferior Care Compared With White Americans? Uneasy Questions and Speculations, The American Journal of Gastroenterology, 2007, 102, 7, 1343

    CrossRef

  95. 95
    Ole H Nielsen, Lars K Munck, Drug Insight: aminosalicylates for the treatment of IBD, Nature Clinical Practice Gastroenterology & Hepatology, 2007, 4, 3, 160

    CrossRef

  96. 96
    Dennis J. Cada, Danial E. Baker, Terri L. Levien, Formulary Drug Reviews - Mesalamine, Hospital Pharmacy, 2007, 42, 6, 543

    CrossRef

  97. 97
    William McLean, Medication adherence initiatives — Part II, Canadian Pharmacists Journal, 2007, 140, 5, 320

    CrossRef

  98. 98
    Petr Červený, Martin Bortlík, Aleš Kuběna, Jiří Vlček, Peter Laszlo Lakatos, Milan Lukáš, Nonadherence in inflammatory bowel disease: Results of factor analysis, Inflammatory Bowel Diseases, 2007, 13, 10
  99. 99
    Srini Tenjarla, Vallente Romasanta, Evelijn Zeijdner, Roberto Villa, Luigi Moro, Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system, Advances in Therapy, 2007, 24, 4, 826

    CrossRef

  100. 100
    Frans Albersnagel, Gerard Dijkstra, Serie: psychologische interventies bij somatische aandoeningen, Psychologie en Gezondheid, jaargang 2007, 2007, 35, 2, 77

    CrossRef

  101. 101
    R. D’Inca, A.T. Garribba, M.G. Vettorato, A. Martin, D. Martines, V. Di Leo, A. Buda, G.C. Sturniolo, Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre, Digestive and Liver Disease, 2007, 39, 6, 524

    CrossRef

  102. 102
    Handbook of Acid-Base Indicators, 2007,

    CrossRef

  103. 103
    Handbook of Acid-Base Indicators, 2007,

    CrossRef

  104. 104
    Isabel Bernal, Eugeni Domènech, Esther Garcia-Planella, Laura Marín, Míriam Mañosa, Mercè Navarro, Eduard Cabré, Miquel A. Gassull, Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, 2006, 51, 12, 2165

    CrossRef

  105. 105
    Fernando Gomollón, Seguridad de los tratamientos en la enfermedad inflamatoria intestinal, Gastroenterología y Hepatología, 2006, 29, 45

    CrossRef

  106. 106
    Laurie Keefer, Tiffany H. Taft, Jennifer L. Kiebles, Gastrointestinal Diseases, Handbook of Psychology, Second Edition,
  107. 107
    Ram W. Sabnis, Erwin Ross, Jutta Köthe, Renate Naumann, Wolfgang Fischer, Wilhelm-Dietrich Mayer, Gerhard Wieland, Ernest J. Newman, Charles M. Wilson, Indicator Reagents, Ullmann's Encyclopedia of Industrial Chemistry,
  108. 108
    Brian G Feagan, John K MacDonald, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, The Cochrane Library,
  109. 109
    Brian G Feagan, John K MacDonald, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, The Cochrane Library,
  110. 110
    Kamal R Mahtani, Carl J Heneghan, Paul P Glasziou, Rafael Perera, Reminder packaging for improving adherence to self-administered long-term medications, The Cochrane Library,